Here are the 10-K annual reports from Goldenwell Biotech Inc (GWLL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GWLL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GWLL filings page.
Goldenwell Biotech, Inc. reports minimal 2025 revenue of $55 from nutraceutical and dietary supplement products and a net loss of $296,471, reflecting very early-stage operations. The company has no active operating facilities and uses its Ohio address only for mail.
As of December 31, 2025, Goldenwell held cash of $26,775, total assets of $36,120, total liabilities of $379,833, and a stockholders’ deficit of $343,713. Management and the auditor highlight substantial doubt about the company’s ability to continue as a going concern. Goldenwell estimates it needs about $5,000,000 and roughly one year to build manufacturing capacity, but currently relies on related-party loans and has three non-employee officers, material weaknesses in internal controls, no independent directors, and no formal cybersecurity risk processes.